CMPX

Compass Therapeutics, Inc.
CAPPED RATING

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc. (CMPX) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Revisions (F). The rating has held at D+ for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.5
EV / EBITDA 0.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -64.6%
Price Return 12M -80.2%
Catalyst Signal 0.00
Market Cap $150.9M
TTM Revenue N/A
Price / Sales N/A
ROE -49.0%

Historical Factor Score Progression

Held D+ for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) D+ (1.5) C- (1.9) D- (0.8) F (0.0) D+ (1.6)
2026-11-04 B+ (3.7) D+ (1.6) C (2.2) D- (0.8) F (0.0) D+ (1.7)
2026-10-28 B+ (3.7) D+ (1.6) C (2.2) D- (0.9) F (0.0) D+ (1.7)
2026-10-21 B+ (3.7) D+ (1.6) C (2.2) D- (0.8) F (0.0) D+ (1.7)
2026-10-14 B+ (3.7) D+ (1.6) C (2.2) D- (0.8) F (0.0) D+ (1.7)
Page 1 of 4